These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat. Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253 [TBL] [Abstract][Full Text] [Related]
7. The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19. Mantzourani C; Vasilakaki S; Gerogianni VE; Kokotos G Expert Opin Drug Discov; 2022 Mar; 17(3):231-246. PubMed ID: 35072549 [TBL] [Abstract][Full Text] [Related]
8. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19. Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356 [TBL] [Abstract][Full Text] [Related]
9. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2). Rahman N; Basharat Z; Yousuf M; Castaldo G; Rastrelli L; Khan H Molecules; 2020 May; 25(10):. PubMed ID: 32408547 [TBL] [Abstract][Full Text] [Related]
10. Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19. Shrimp JH; Janiszewski J; Chen CZ; Xu M; Wilson KM; Kales SC; Sanderson PE; Shinn P; Schneider R; Itkin Z; Guo H; Shen M; Klumpp-Thomas C; Michael SG; Zheng W; Simeonov A; Hall MD ACS Infect Dis; 2022 Jun; 8(6):1191-1203. PubMed ID: 35648838 [TBL] [Abstract][Full Text] [Related]
11. Serine Protease Inhibitors Restrict Host Susceptibility to SARS-CoV-2 Infections. Rosendal E; Mihai IS; Becker M; Das D; Frängsmyr L; Persson BD; Rankin GD; Gröning R; Trygg J; Forsell M; Ankarklev J; Blomberg A; Henriksson J; Överby AK; Lenman A mBio; 2022 Jun; 13(3):e0089222. PubMed ID: 35532162 [TBL] [Abstract][Full Text] [Related]
12. Reactive Centre Loop Mutagenesis of SerpinB3 to Target TMPRSS2 and Furin: Inhibition of SARS-CoV-2 Cell Entry and Replication. Singh S; O'Reilly S; Gewaid H; Bowie AG; Gautier V; Worrall DM Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293378 [TBL] [Abstract][Full Text] [Related]
13. Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture. Wettstein L; Knaff PM; Kersten C; Müller P; Weil T; Conzelmann C; Müller JA; Brückner M; Hoffmann M; Pöhlmann S; Schirmeister T; Landfester K; Münch J; Mailänder V Commun Biol; 2022 Jul; 5(1):681. PubMed ID: 35804152 [TBL] [Abstract][Full Text] [Related]
14. An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19. Shrimp JH; Kales SC; Sanderson PE; Simeonov A; Shen M; Hall MD ACS Pharmacol Transl Sci; 2020 Oct; 3(5):997-1007. PubMed ID: 33062952 [TBL] [Abstract][Full Text] [Related]
15. An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19. Shrimp JH; Kales SC; Sanderson PE; Simeonov A; Shen M; Hall MD bioRxiv; 2020 Aug; ():. PubMed ID: 32596694 [TBL] [Abstract][Full Text] [Related]
17. Molecular docking analysis reveals the functional inhibitory effect of Genistein and Quercetin on TMPRSS2: SARS-COV-2 cell entry facilitator spike protein. Manjunathan R; Periyaswami V; Mitra K; Rosita AS; Pandya M; Selvaraj J; Ravi L; Devarajan N; Doble M BMC Bioinformatics; 2022 May; 23(1):180. PubMed ID: 35578172 [TBL] [Abstract][Full Text] [Related]
18. Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges. Mahmoud IS; Jarrar YB Mol Biol Rep; 2021 May; 48(5):4667-4675. PubMed ID: 34023987 [TBL] [Abstract][Full Text] [Related]
19. In Silico Screening of Novel TMPRSS2 Inhibitors for Treatment of COVID-19. Wang S; Fang X; Wang Y Molecules; 2022 Jun; 27(13):. PubMed ID: 35807455 [TBL] [Abstract][Full Text] [Related]
20. Screening strategy of TMPRSS2 inhibitors by FRET-based enzymatic activity for TMPRSS2-based cancer and COVID-19 treatment. Chen Y; Huang WC; Yang CS; Cheng FJ; Chiu YF; Chen HF; Huynh TK; Huang CF; Chen CH; Wang HC; Hung MC Am J Cancer Res; 2021; 11(3):827-836. PubMed ID: 33791156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]